Pertuzumab plus Trastuzumab plus Docetaxel for metastatic breast cancer. N Eng J Med, Dec 2011.
Baselga, J., et al.
http://www.nejm.org/doi/full/10.1056/NEJMoa1113216#t=article
The anti–human epidermal growth factor receptor 2 (HER2) humanized monoclonal antibody trastuzumab improves the outcome in patients with HER2-positive metastatic breast cancer. However, most cases of advanced disease eventually progress.
